Expert opinion on pharmacotherapy · 2009
Pharmacotherapy of patients with schizophrenia and substance abuse.
СтатьяПоддержка исследования: вне правительства СШАСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wobrock Thomas, Soyka Michael
Аннотация
BACKGROUND: Comorbid substance-use disorder in schizophrenia patients is associated with poor clinical and functional outcome.
OBJECTIVE: To provide evidence-based pharmacological treatment recommendations to improve the disease course of this patient group.
METHODS: A comprehensive systematic review of the pharmacological studies in this subgroup of patients was performed and the available studies were discussed from the standpoint of evidence-based medicine.
RESULTS/CONCLUSION: Slight advantages were found for second-generation antipsychotic agents over conventional antipsychotics with regard to improvement of distinct psychopathological symptoms, reduced craving, and greater reduction of substance use; these findings are mainly derived from open studies or case series. Additional treatment with antidepressants, depending on the patient's psychopathology, as well as with anti-craving agents should be considered.
OBJECTIVE: To provide evidence-based pharmacological treatment recommendations to improve the disease course of this patient group.
METHODS: A comprehensive systematic review of the pharmacological studies in this subgroup of patients was performed and the available studies were discussed from the standpoint of evidence-based medicine.
RESULTS/CONCLUSION: Slight advantages were found for second-generation antipsychotic agents over conventional antipsychotics with regard to improvement of distinct psychopathological symptoms, reduced craving, and greater reduction of substance use; these findings are mainly derived from open studies or case series. Additional treatment with antidepressants, depending on the patient's psychopathology, as well as with anti-craving agents should be considered.